Methylprednisolone for acute relapses of multiple sclerosis can oral replace intravenous administration?

CNS Drugs

Volumn 10, Issue 4, 1998, Pages 233-238

  Uitdehaag, Bernard M J ^a   Barkhof, Frederik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE;

COST BENEFIT ANALYSIS; DEMYELINATING DISEASE; DRUG ABUSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REVIEW; STATISTICAL ANALYSIS;

EID: 0031771419     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810040-00001     Document Type: Review

References (26)

1. Merritt HH, Glaser GH, Herrmann C. A study of the short- and long-term effects of adrenal steroids on the clinical patterns of multiple sclerosis. Ann NY Acad Sci 1954; 58: 625-32
2. Rose AS, Kuzma JW, Kurtzke JF, et al. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo final report. Neurology 1970; 20 (Pt II): 1-59
3. Snyder BD, Lakatua DJ, Doe RP. ACTH-induced cortisol production in multiple sclerosis. Ann Neurol 1981; 10: 388-9
4. Defer G-L, Barré J, Ledudal P, et al. Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. Eur Neurol 1995; 35: 143-8
5. Barnes MP, Bateman DE, Cleland PG, et al. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 1985; 48: 157-9
6. Milanese C, La Mantia L, Salmaggi A, et al. Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts: clinical, cerebrospinal fluid and neurophysiological results. Eur Neurol 1989; 29: 10-4
7. Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989; 39: 969-71
8. Daynes RA, Araneo BA. Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin 2 and interleukin 4. Eur J Immunol 1989; 19: 2319-25
9. Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993; 14: 436-41
10. Schwartzman RA, Cidlowski JA. Glucocorticoid-induced apoptosis of lymphoid cells. Int Arch Allergy Immunol 1994; 105: 347-54
11. Hirschberg H, Hirschberg T, Nousiainen H, et al. The effects of corticosteroids on the antigen presenting properties of human munocytes and endothelial cells. Clin Immunol Immunopathol 1982; 23: 577-85
12. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286-90
13. Scheiman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-6
14. Funder JW. Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Annu Rev Med 1997; 48: 231-40
15. Beck RW, Cleary PA, Anderson Jr MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326: 581-8
16. Dowling PC, Bosch VV, Cook SD. Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis. Neurology 1980; 30: 33-6
17. Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986; 36: 238-43
18. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511-6
19. Cazzato G, Mesiano T, Antonello R, et al. Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur Neurol 1995; 35: 193-8
20. Lyons PR, Newman PK, Saunders M. Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. J Neurol Neurosurg Psychiatry 1988; 51: 285-7
21. Tourtelotte WW, Haerer AF. Use of oral corticosteroid in the treatment of multiple sclerosis. Arch Neurol 1965; 12: 536-45
22. Alam SM, Kyriakides T, Lawden M, et al. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993; 56: 1219-20
23. Barnes D, Hughes RAC, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349: 902-6
24. DeKeyser J, Zwanikken C. Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis [letter]. Lancet 1997; 349: 1696
25. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996; 39: 6-16
26. Barkhof F, Frequin ST, Hommes OR, et al. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992; 42: 63-7